+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Africa Generic Pharmaceutical Market Size, Share & Trends Analysis Report By Type (Simple Generics, Specialty Generics), By Route Of Administration, By Product, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 102 Pages
  • September 2023
  • Region: Africa
  • Grand View Research
  • ID: 5893315
The Africa generic pharmaceutical market size is estimated to reach USD 9.29 billion by 2030. The market is projected to grow at a CAGR of 4.32% from 2023 to 2030. The market is positioned for significant growth opportunities driven by several compelling factors. One crucial factor is the region's growing population and increasing healthcare needs, which have led to rising demand for affordable medicines. However, limited healthcare budgets have made it challenging for many people to access expensive branded drugs, creating an ideal environment for the flourishing of generic pharmaceuticals. These generics play a critical role in addressing the healthcare affordability challenges across Africa, making essential medications more accessible to a broader population.

Another advantage of generic drugs is their potential for high-volume sales. Africa's large patient population, coupled with the prevalence of chronic diseases like cardiovascular disorders, diabetes, and infectious diseases, presents a substantial market for generic medicines. These drugs not only fulfill immediate healthcare demands but also contribute to improving overall health outcomes by providing cost-effective solutions.

As the region's evolving healthcare landscape, the market in Africa is poised to assume a pivotal role in shaping the future of healthcare delivery. By offering affordable medications and meeting the needs of the growing patient population, these medicines will contribute significantly to enhancing healthcare accessibility and overall health outcomes for the population across the continent.

Furthermore, growing health concerns, emerging pharmaceutical innovation, and growing research & development activities contribute to market revenue. Pharmaceutical drug products have become increasingly important in the region, attributed to increasing competition between multinational and local pharmaceutical companies vying for a higher share. Therefore, continued generics innovation to expand their presence has benefited the market. For instance, in March 2023, MSN Group introduced Fesobig, the world's first bioequivalent generic of Feroteodine Fumarate, an effective treatment for Overactive Bladder (OAB) and Urinary Incontinence (UI). Priced at approximately USD 15 per tablet in the U.S., Fesobig will soon be available globally, pending regulatory approvals. This development holds significant potential for the market, offering cost-effective alternatives for patients in need.

The key market participants are engaged in strategies such as partnerships, agreements, mergers & acquisitions, collaborations, and launches, among others, to expand their global footprints and portfolios. For instance, in May 2023, Cipla Inc. announced its plans to produce a generic version of a revolutionary HIV-prevention drug, long-acting cabotegravir (CAB-LA), in South Africa. The manufacturing would take place at Cipla's facilities located in Benoni or Durban. This significant development marked the first time that an affordable variant of this breakthrough medication would be manufactured in South Africa. Consequently, it has the potential to provide millions of individuals at risk of HIV infection in Africa with access to a bimonthly injection that would significantly reduce their chances of contracting the virus.

Africa Generic Pharmaceutical Market Report Highlights

  • Based on type, the simple generics segment held the largest revenue share of 64.67% in 2022 owing to the high penetration rate and availability coupled with increased cardiovascular, central nervous system disorders, and diabetes incidences. Biosimilars are anticipated to grow at the fastest CAGR of 6.68% over the forecast period
  • In terms of application, the cardiovascular diseases segment dominated the market in 2022 with a revenue share of 16.84%. The growth is attributed to the growing burden of cardiovascular diseases and the strong demand for various generic pharmaceuticals
  • Based on product, the small molecule segment dominated the market in 2022 owing to low cost, effectiveness, and a rising number of FDA approvals
  • Based on the route of administration, the oral segment is anticipated to dominate the market in 2022 as this route of administration is more convenient, effective, and safe at a low cost
  • In terms of distribution channel, the retail pharmacies segment dominated the market in 2022 with a revenue share of over 45.20% due to the wide range of drug availability, rapid dramatic changes in retail pharmacies' demand, and growing retail pharmacy competition
  • In terms of region, South Africa dominated the market in 2022 with the largest revenue share of 22.42% owing to factors such as potential demand for generic pharmaceuticals over branded drugs, the growing burden of cardiovascular diseases, and rising new product launches in the region

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Product Type Segment
1.1.1.2. Drug Class Segment
1.1.1.3. Application Segment
1.1.1.4. Distribution Channel Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Type and Product Snapshot
2.3. Application and Distribution Channel Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Emerging chronic diseases patients
3.2.1.2. Increasing number of new FDA generics approvals
3.2.2. Market Restraint Analysis
3.2.2.1. High cost of production
3.3. SWOT Analysis, by Factor
3.4. Industry Analysis- Porter’s
Chapter 4. Type Business Analysis
4.1. Africa Generic Pharmaceutical Market: Type Movement Analysis
4.2. Simple Generics
4.2.1. Simple Generics Market, 2018 - 2030 (USD Million)
4.3. Specialty Generics
4.3.1. Specialty Generics Market, 2018 - 2030 (USD Million)
4.4. Biosimilars
4.4.1. Biosimilars Market, 2018 - 2030 (USD Million)
Chapter 5. Application Business Analysis
5.1. Africa Generic Pharmaceutical Market: Application Movement Analysis
5.2. Central Nervous System Disorders
5.2.1. Central Nervous System Disorders Market, 2018 - 2030 (USD Million)
5.3. Respiratory Diseases
5.3.1. Respiratory Diseases Market, 2018 - 2030 (USD Million)
5.4. Hormones & Related Diseases
5.4.1. Hormones & Related Diseases Market, 2018 - 2030 (USD Million)
5.5. Gastrointestinal Diseases
5.5.1. Gastrointestinal Diseases Market, 2018 - 2030 (USD Million)
5.6. Cardiovascular Diseases
5.6.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
5.7. Infectious Diseases
5.7.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
5.8. Cancer
5.8.1. Cancer Market, 2018 - 2030 (USD Million)
5.9. Diabetes
5.9.1. Diabetes Market, 2018 - 2030 (USD Million)
5.10. Others
5.10.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Product Business Analysis
6.1. Africa Generic Pharmaceutical Market: Product Movement Analysis
6.2. Small Molecule
6.2.1. Small Molecule Market, 2018 - 2030 (USD Million)
6.3. Large Molecule
6.3.1. Large Molecule Market, 2018 - 2030 (USD Million)
Chapter 7. Route of Administration Business Analysis
7.1. Africa Generic Pharmaceutical Market: Route of Administration Movement Analysis
7.2. Oral
7.2.1. Oral Market, 2018 - 2030 (USD Million)
7.3. Injectable
7.3.1. Injectable Molecule Market, 2018 - 2030 (USD Million)
7.4. Inhalable
7.4.1. Inhalable Molecule Market, 2018 - 2030 (USD Million)
7.5. Others
7.5.1. Others Molecule Market, 2018 - 2030 (USD Million)
Chapter 8. Distribution Channel Business Analysis
8.1. Africa Generic Pharmaceutical Market: Distribution Channel Movement Analysis
8.2. Retail Pharmacies
8.2.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
8.3. Hospital Pharmacies
8.3.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
8.4. Others
8.4.1. Others Market, 2018 - 2030 (USD Million)
Chapter 9. Africa Generic Pharmaceutical Market: Regional Business Analysis
9.1. Regional Market Snapshot
9.2. Africa
9.2.1. Africa Generic Pharmaceutical Market Estimates And Forecast, 2018 - 2030 (USD Million)
9.2.2. Botswana
9.2.2.1. Botswana Generic Pharmaceutical Market, 2018 - 2030 (USD Million)
9.2.2.2. Key Country Dynamics
9.2.2.3. Regulatory Framework
9.2.2.4. Reimbursement Scenario
9.2.2.5. Competitive Scenario
9.2.3. Namibia
9.2.3.1. Namibia Generic Pharmaceutical Market, 2018 - 2030 (USD Million)
9.2.3.2. Key Country Dynamics
9.2.3.3. Regulatory Framework
9.2.3.4. Reimbursement Scenario
9.2.3.5. Competitive Scenario
9.2.4. Zimbabwe
9.2.4.1. Zimbabwe Generic Pharmaceutical Market, 2018 - 2030 (USD Million)
9.2.4.2. Key Country Dynamics
9.2.4.3. Regulatory Framework
9.2.4.4. Reimbursement Scenario
9.2.4.5. Competitive Scenario
9.2.5. Zambia
9.2.5.1. Zambia Generic Pharmaceutical Market, 2018 - 2030 (USD Million)
9.2.5.2. Key Country Dynamics
9.2.5.3. Regulatory Framework
9.2.5.4. Reimbursement Scenario
9.2.5.5. Competitive Scenario
9.2.6. Tanzania
9.2.6.1. Tanzania Generic Pharmaceutical Market, 2018 - 2030 (USD Million)
9.2.6.2. Key Country Dynamics
9.2.6.3. Regulatory Framework
9.2.6.4. Reimbursement Scenario
9.2.6.5. Competitive Scenario
9.2.7. Rwanda
9.2.7.1. Rwanda Generic Pharmaceutical Market, 2018 - 2030 (USD Million)
9.2.7.2. Key Country Dynamics
9.2.7.3. Regulatory Framework
9.2.7.4. Reimbursement Scenario
9.2.7.5. Competitive Scenario
9.2.8. Ghana
9.2.8.1. Ghana Generic Pharmaceutical Market, 2018 - 2030 (USD Million)
9.2.8.2. Key Country Dynamics
9.2.8.3. Regulatory Framework
9.2.8.4. Reimbursement Scenario
9.2.8.5. Competitive Scenario
9.2.9. Nigeria
9.2.9.1. Nigeria Generic Pharmaceutical Market, 2018 - 2030 (USD Million)
9.2.9.2. Key Country Dynamics
9.2.9.3. Regulatory Framework
9.2.9.4. Reimbursement Scenario
9.2.9.5. Competitive Scenario
9.2.10. South Africa
9.2.10.1. South Africa Generic Pharmaceutical Market, 2018 - 2030 (USD Million)
9.2.10.2. Key Country Dynamics
9.2.10.3. Regulatory Framework
9.2.10.4. Reimbursement Scenario
9.2.10.5. Competitive Scenario
9.2.11. Angola
9.2.11.1. Angola Generic Pharmaceutical Market, 2018 - 2030 (USD Million)
9.2.11.2. Key Country Dynamics
9.2.11.3. Regulatory Framework
9.2.11.4. Reimbursement Scenario
9.2.11.5. Competitive Scenario
9.2.12. Mozambique
9.2.12.1. Mozambique Generic Pharmaceutical Market, 2018 - 2030 (USD Million)
9.2.12.2. Key Country Dynamics
9.2.12.3. Regulatory Framework
9.2.12.4. Reimbursement Scenario
9.2.12.5. Competitive Scenario
9.2.13. Cameroon
9.2.13.1. Cameroon Generic Pharmaceutical Market, 2018 - 2030 (USD Million)
9.2.13.2. Key Country Dynamics
9.2.13.3. Regulatory Framework
9.2.13.4. Reimbursement Scenario
9.2.13.5. Competitive Scenario
9.2.14. Senegal
9.2.14.1. Senegal Generic Pharmaceutical Market, 2018 - 2030 (USD Million)
9.2.14.2. Key Country Dynamics
9.2.14.3. Regulatory Framework
9.2.14.4. Reimbursement Scenario
9.2.14.5. Competitive Scenario
9.2.15. Ivory Coast
9.2.15.1. Ivory Coast Generic Pharmaceutical Market, 2018 - 2030 (USD Million)
9.2.15.2. Key Country Dynamics
9.2.15.3. Regulatory Framework
9.2.15.4. Reimbursement Scenario
9.2.15.5. Competitive Scenario
9.2.16. Rest Sub-Saharan Africa
9.2.16.1. Rest Sub-Saharan Africa Generic Pharmaceutical Market, 2018 - 2030 (USD Million)
9.2.16.2. Key Country Dynamics
9.2.16.3. Regulatory Framework
9.2.16.4. Reimbursement Scenario
9.2.16.5. Competitive Scenario
9.3. Rest of Africa and Sub-Saharan Africa
9.3.1. Rest of Africa and Sub-Saharan Africa Generic Pharmaceutical Market, 2018 - 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Strategy Mapping
10.3. Company Market Share Analysis, 2022
10.4. Company Profiles/Listing
10.4.1. Abbott Laboratories
10.4.1.1. Overview
10.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.1.3. Product Benchmarking
10.4.1.4. Strategic Initiatives
10.4.2. F. Hoffmann-La Roche Ltd
10.4.2.1. Overview
10.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.2.3. Product Benchmarking
10.4.2.4. Strategic Initiatives
10.4.3. Novartis AG
10.4.3.1. Overview
10.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.3.3. Product Benchmarking
10.4.3.4. Strategic Initiatives
10.4.4. Cipla South Africa
10.4.4.1. Overview
10.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.4.3. Product Benchmarking
10.4.4.4. Strategic Initiatives
10.4.5. Aspen Holdings
10.4.5.1. Overview
10.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.5.3. Product Benchmarking
10.4.5.4. Strategic Initiatives
10.4.6. Teva Pharmaceutical Industries Ltd.
10.4.6.1. Overview
10.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.6.3. Product Benchmarking
10.4.6.4. Strategic Initiatives
10.4.7. Endo International plc
10.4.7.1. Overview
10.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.7.3. Product Benchmarking
10.4.7.4. Strategic Initiatives
10.4.8. Viatris, Inc.
10.4.8.1. Overview
10.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.8.3. Product Benchmarking
10.4.8.4. Strategic Initiatives
10.4.9. Sun Pharmaceutical Industries Ltd.
10.4.9.1. Overview
10.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.9.3. Product Benchmarking
10.4.9.4. Strategic Initiatives
10.4.10. Lupin
10.4.10.1. Overview
10.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.10.3. Product Benchmarking
10.4.10.4. Strategic Initiatives
10.4.11. AbbVie Inc.
10.4.11.1. Overview
10.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.11.3. Product Benchmarking
10.4.11.4. Strategic Initiatives
10.4.12. Aurobindo Pharma
10.4.12.1. Overview
10.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.12.3. Product Benchmarking
10.4.12.4. Strategic Initiatives
10.4.13. Sanofi
10.4.13.1. Overview
10.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.13.3. Product Benchmarking
10.4.13.4. Strategic Initiatives
10.4.14. Hikma Pharmaceuticals
10.4.14.1. Overview
10.4.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.14.3. Product Benchmarking
10.4.14.4. Strategic Initiatives
10.4.15. Dr. Reddy’s Laboratories Ltd.
10.4.15.1. Overview
10.4.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.15.3. Product Benchmarking
10.4.15.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 List of Secondary Sources
Table 4 List of Abbreviations
Table 5 Africa Generic Pharmaceutical Market, By Region, 2018 - 2030 (USD Million)
Table 6 Africa Generic Pharmaceutical Market, By Country, 2018 - 2030 (USD Million)
Table 7 Africa Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 8 Africa Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 9 Africa Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 10 Africa Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 11 Africa Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 12 Botswana Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 13 Botswana Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 14 Botswana Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 15 Botswana Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 16 Botswana Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 17 Namibia Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 18 Namibia Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 19 Namibia Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 20 Namibia Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 21 Namibia Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 22 Zimbabwe Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 23 Zimbabwe Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 24 Zimbabwe Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 25 Zimbabwe Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 26 Zimbabwe Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 27 Zambia Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 28 Zambia Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 29 Zambia Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 30 Zambia Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 31 Zambia Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 32 Tanzania Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 33 Tanzania Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 34 Tanzania Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 35 Tanzania Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 36 Tanzania Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 37 Rwanda Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 38 Rwanda Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 39 Rwanda Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 40 Rwanda Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 41 Rwanda Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 42 Ghana Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 43 Ghana Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 44 Ghana Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 45 Ghana Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 46 Ghana Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 47 Nigeria Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 48 Nigeria Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 49 Nigeria Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 50 Nigeria Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 51 Nigeria Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 52 South Africa Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 53 South Africa Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 54 South Africa Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 55 South Africa Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 56 South Africa Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 57 Angola Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 58 Angola Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 59 Angola Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 60 Angola Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 61 Angola Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 62 Mozambique Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 63 Mozambique Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 64 Mozambique Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 65 Mozambique Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 66 Mozambique Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 67 Cameroon Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 68 Cameroon Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 69 Cameroon Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 70 Cameroon Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 71 Cameroon Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 72 Senegal Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 73 Senegal Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 74 Senegal Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 75 Senegal Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 76 Senegal Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 77 Ivory Coast Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 78 Ivory Coast Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 79 Ivory Coast Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 80 Ivory Coast Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 81 Ivory Coast Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 82 Rest Sub-Saharan Africa Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 83 Rest Sub-Saharan Africa Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 84 Rest Sub-Saharan Africa Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 85 Rest Sub-Saharan Africa Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 86 Rest Sub-Saharan Africa Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 87 Rest of Africa Generic Pharmaceutical Market, By Type, 2018 - 2030 (USD Million)
Table 88 Rest of Africa Generic Pharmaceutical Market, By Application, 2018 - 2030 (USD Million)
Table 89 Rest of Africa Generic Pharmaceutical Market, By Product, 2018 - 2030 (USD Million)
Table 90 Rest of Africa Generic Pharmaceutical Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 91 Rest of Africa Generic Pharmaceutical Market, By Distribution Channel, 2018 - 2030 (USD Million)
Table 92 Company market share, 2022
List of Figures
Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Africa Generic Pharmaceutical Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 Africa generic pharmaceutical market: Type outlook and key takeaways
Fig. 15 Africa generic pharmaceutical market: Type movement analysis & market share 2022 & 2030
Fig. 16 Simple generics market, 2018 - 2030 (USD Million)
Fig. 17 Specialty generics market, 2018 - 2030 (USD Million)
Fig. 18 Biosimilars market, 2018 - 2030 (USD Million)
Fig. 19 Africa generic pharmaceutical market: Application outlook and key takeaways
Fig. 20 Africa generic pharmaceutical market: Application movement analysis & market share 2022 & 2030
Fig. 21 Central nervous system disorders market, 2018 - 2030 (USD Million)
Fig. 22 Respiratory diseases market, 2018 - 2030 (USD Million)
Fig. 23 Hormones & related diseases market, 2018 - 2030 (USD Million)
Fig. 24 Gastrointestinal diseases market, 2018 - 2030 (USD Million)
Fig. 25 Cardiovascular diseases market, 2018 - 2030 (USD Million)
Fig. 26 Infectious diseases market, 2018 - 2030 (USD Million)
Fig. 27 Cancer market, 2018 - 2030 (USD Million)
Fig. 28 Diabetes market, 2018 - 2030 (USD Million)
Fig. 29 Others market, 2018 - 2030 (USD Million)
Fig. 30 Africa generic pharmaceutical market: Product outlook and key takeaways
Fig. 31 Africa generic pharmaceutical market: Product movement analysis & market share 2022 & 2030
Fig. 32 Small molecule market, 2018 - 2030 (USD Million)
Fig. 33 Large molecule market, 2018 - 2030 (USD Million)
Fig. 34 Africa generic pharmaceutical market: Route of Administration outlook and key takeaways
Fig. 35 Africa generic pharmaceutical market: Route of Administration movement analysis & market share 2022 & 2030
Fig. 36 Oral market, 2018 - 2030 (USD Million)
Fig. 37 Injectable market, 2018 - 2030 (USD Million)
Fig. 38 Inhalable market, 2018 - 2030 (USD Million)
Fig. 39 Others market, 2018 - 2030 (USD Million)
Fig. 40 Africa generic pharmaceutical market: Distribution channel outlook and key takeaways
Fig. 41 Africa generic pharmaceutical market: Distribution channel movement analysis & market share 2022 & 2030
Fig. 42 Retail pharmacies market, 2018 - 2030 (USD Million)
Fig. 43 Hospital pharmacies market, 2018 - 2030 (USD Million)
Fig. 44 Others market, 2018 - 2030 (USD Million)
Fig. 45 Regional marketplace: Key takeaways
Fig. 46 Africa generic pharmaceutical market: Regional movement analysis
Fig. 47 Africa generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 48 Botswana generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 49 Namibia generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 50 Zimbabwe generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 51 Zambia generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 52 Tanzania generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 53 Rwanda generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 54 Ghana generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 55 Nigeria generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 56 South Africa generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 57 Angola generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 58 Mozambique generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 59 Cameroon generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 60 Senegal generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 61 Ivory Coast generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 62 Rest Sub-Saharan Africa generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 63 Rest of Africa and Sub-Saharan Africa generic pharmaceutical market, 2018 - 2030 (USD Million)
Fig. 64 Strategy framework

Companies Mentioned

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Cipla South Africa
  • Aspen Holdings
  • Teva Pharmaceutical Industries Ltd.
  • Endo International plc
  • Viatris, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Lupin
  • AbbVie Inc.
  • Aurobindo Pharma
  • Sanofi
  • Hikma Pharmaceuticals
  • Dr. Reddy’s Laboratories Ltd.

Methodology

Loading
LOADING...

Table Information